Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, announced that the Company will participate in the following upcoming investor conferences:

• 2025 Wells Fargo Healthcare Conference, including one-on-one meetings on Wednesday, September 3, 2025 in Boston, Massachusetts
  
• Cantor Global Healthcare Conference 2025, including a fireside chat at 10:55 AM ET on Thursday, September 4, 2025 in New York, New York
  

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Precision AQ
212.362.1200
[email protected]

You May Also Be Interested In

• Bitcoin Bull Run Returns? Trade Crypto with 100x Leverage, No KYC and Exclusive Bonuses on BexBack
• Form 8.3 -DCC plc
• LHV Group's own share acquisition transactions